Novartis (Leniolisib) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Novartis (Leniolisib) General Information
Description
A phase 3 rare disease drug intended for the treatment of activated PI3K delta syndrome.
Contact Information
Corporate Office
- Switzerland
Corporate Office
- Switzerland
Novartis (Leniolisib) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Novartis (Leniolisib) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Novartis (Leniolisib) FAQs
-
Where is Novartis (Leniolisib) headquartered?
Novartis (Leniolisib) is headquartered in Switzerland.
-
What industry is Novartis (Leniolisib) in?
Novartis (Leniolisib)’s primary industry is Buildings and Property.
-
Is Novartis (Leniolisib) a private or public company?
Novartis (Leniolisib) is a Private company.
-
What is the current valuation of Novartis (Leniolisib)?
The current valuation of Novartis (Leniolisib) is .
-
What is Novartis (Leniolisib)’s current revenue?
The current revenue for Novartis (Leniolisib) is .
-
Who are Novartis (Leniolisib)’s investors?
Novartis has invested in Novartis (Leniolisib).
-
When was Novartis (Leniolisib) acquired?
Novartis (Leniolisib) was acquired on 13-Aug-2019.
-
Who acquired Novartis (Leniolisib)?
Novartis (Leniolisib) was acquired by Pharming Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process